Testing Status of AZT + Rifampin (AIDS Initiative) M930017
CASRN: AZTRIFAMPIN
Secondary:
- 30516-87-1 - 3'-Azido-3'-deoxythymidine (AIDS)
- 30516-87-1 - AZT transplacental carcinogenesis study
- 13292-46-1 - Rifampin
Short-Term Toxicity
- 13 weeks (Gavage)
(C93002)
Completed
- Mice: B6C3F1
Special Studies
- Toxicokinetic Study (Gavage; Intravenous)
(S0553)
Completed
- Male and Female Mice: B6C3F1
- Dose: IV: 100 MG AZT/KG BW; PO: 200 MG AZT/KG BW & 200 MG AZT + 200 MG RIFAMPIN/KG BW Repeated dose study: all doses for AZT and RIF are 100 mg/kg BW.
- Toxicokinetic Study (Gavage; Intravenous)
(S0643)
Completed
- Male and Female Mice: B6C3F1
- Dose: (all routes) 100 mg/kg AZT. 100 mg/kg Rif [M].